AI assistant
CSL Ltd. — Regulatory Filings 2021
Dec 12, 2021
17854_rns_2021-12-12_de31c4bc-31da-479b-b239-b00e42a83855.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
For immediate release
13 December 2021
==> picture [205 x 32] intentionally omitted <==
==> picture [58 x 30] intentionally omitted <==
==> picture [262 x 27] intentionally omitted <==
Response to media speculation
CSL Limited (ASX:CSL; USOTC:CSLLY) notes the media speculation about a potential transaction involving Swiss based Vifor Pharma Ltd.
CSL confirms that it is in discussions with Vifor Pharma Ltd regarding a potential transaction, however at this time there remains no certainty that any transaction will result and, if a transaction does result, when such a transaction would occur.
CSL will keep the market informed in accordance with its continuous disclosure obligations, and otherwise does not intend to comment on such matters.
Authorised by Fiona Mead Company Secretary
FURTHER INFORMATION
For further information, please contact:
Investors: Media: Mark Dehring Jemimah Brennan Head of Investor Relations Head of Communications, Asia Pacific CSL Limited CSL Limited Telephone: +613 9389 3407 Mobile +61 412 635 483 Email: [email protected] Email: [email protected]
==> picture [99 x 7] intentionally omitted <==